MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regentis Biomaterials Ltd. Ordinary Shares (NY:RGNT)

1.830 +0.020 (+1.10%)
Official Closing Price Updated: 4:10 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,997
Open 1.860
Bid (Size) 1.780 (2,100)
Ask (Size) 1.920 (100)
Prev. Close 1.810
Today's Range 1.800 - 1.880
52wk Range 1.232 - 15.50
Shares Outstanding 24,114,610
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Regentis Biomaterials Is Addressing the ‘Short-Term Relief, Long-Term Failure’ Problem in Knee Cartilage Repair
Via Investor Brand Network
Regentis Biomaterials and the Shift from Symptom Management to Structural Repair in Knee Cartilage Care
Via Investor Brand Network

Performance

YTD
-73.1%
-73.1%
1 Month
-10.3%
-10.3%
3 Month
-60.0%
-60.0%
6 Month
-39.0%
-39.0%
1 Year
-75.6%
-75.6%

More News

Read More
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) CEO Discusses GelrinC(R), U.S. Pivotal Study and European Commercialization on BioMedWire Podcast
Via Investor Brand Network
MissionIRNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Into Pivotal Stage of Development
Via Investor Brand Network
Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports First Half 2026 Results, Advances GelrinC(R) Pivotal Trial
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair
Via Investor Brand Network
News headline image
Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
From Regentis Biomaterials Ltd
Via ACCESS Newswire
NetworkNewsBreaks – Regentis Biomaterials Ltd.’s (NYSE American: RGNT) GelrinC Advances Toward New Era of Regenerative Orthopedic Care
Via Investor Brand Network
MissionIRNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands GelrinC Clinical and Commercial Pathways
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Marks Key IP Milestone for GelrinC Manufacturing
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial Case for GelrinC in Multi-Billion Knee Cartilage Repair Market
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market
Via Investor Brand Network
Topics Intellectual Property
NetworkNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Via Investor Brand Network
Surgeon, Payer, Patient Win: The Economic and Workflow Advantages Positioning GelrinC as a New Standard of Care for Knee Cartilage Repair
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair
Via Investor Brand Network
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Targets $3 Billion Cartilage Repair Market with Cell-Free Gelrin C
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Clinical and Regulatory Milestones
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Receives Japan Patent Allowance for GelrinC Manufacturing Technology
Via Investor Brand Network
Topics Intellectual Property
News headline image
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
From Regentis Biomaterials Ltd
Via ACCESS Newswire
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process
Via Investor Brand Network
News headline image
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
From Regentis Biomaterials Ltd
Via ACCESS Newswire
The $15 Billion Knee OA Spending Gap: Why Gelrin C Is the Smartest Investment in Cartilage Economics
Via Investor Brand Network

Frequently Asked Questions

Is Regentis Biomaterials Ltd. Ordinary Shares publicly traded?
Yes, Regentis Biomaterials Ltd. Ordinary Shares is publicly traded.
What exchange does Regentis Biomaterials Ltd. Ordinary Shares trade on?
Regentis Biomaterials Ltd. Ordinary Shares trades on the New York Stock Exchange
What is the ticker symbol for Regentis Biomaterials Ltd. Ordinary Shares?
The ticker symbol for Regentis Biomaterials Ltd. Ordinary Shares is RGNT on the New York Stock Exchange
What is the current price of Regentis Biomaterials Ltd. Ordinary Shares?
The current price of Regentis Biomaterials Ltd. Ordinary Shares is 1.830
When was Regentis Biomaterials Ltd. Ordinary Shares last traded?
The last trade of Regentis Biomaterials Ltd. Ordinary Shares was at 10/01/26 04:10 PM ET
What is the market capitalization of Regentis Biomaterials Ltd. Ordinary Shares?
The market capitalization of Regentis Biomaterials Ltd. Ordinary Shares is 44.13M
How many shares of Regentis Biomaterials Ltd. Ordinary Shares are outstanding?
Regentis Biomaterials Ltd. Ordinary Shares has 44M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story